Yousif Capital Management LLC Sells 7,799 Shares of DexCom, Inc. (NASDAQ:DXCM)

Yousif Capital Management LLC cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 11.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,071 shares of the medical device company’s stock after selling 7,799 shares during the period. Yousif Capital Management LLC’s holdings in DexCom were worth $7,330,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Stableford Capital II LLC increased its position in shares of DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after purchasing an additional 88 shares during the period. Valley National Advisers Inc. grew its position in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. FORVIS Wealth Advisors LLC grew its position in DexCom by 0.7% in the fourth quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock valued at $2,033,000 after acquiring an additional 110 shares during the period. Cary Street Partners Investment Advisory LLC grew its position in DexCom by 11.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock valued at $108,000 after acquiring an additional 115 shares during the period. Finally, HM Payson & Co. grew its position in DexCom by 8.5% in the third quarter. HM Payson & Co. now owns 1,480 shares of the medical device company’s stock valued at $138,000 after acquiring an additional 116 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the sale, the chief operating officer now directly owns 273,913 shares in the company, valued at $36,816,646.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Jereme M. Sylvain sold 11,661 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total transaction of $1,567,355.01. Following the completion of the transaction, the chief financial officer now directly owns 85,534 shares in the company, valued at $11,496,624.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,639 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the transaction, the chief operating officer now owns 273,913 shares of the company’s stock, valued at $36,816,646.33. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock worth $25,530,859 over the last ninety days. 0.41% of the stock is currently owned by corporate insiders.

DexCom Trading Up 0.1 %

NASDAQ:DXCM opened at $138.00 on Thursday. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00. The business’s 50-day moving average price is $130.58 and its two-hundred day moving average price is $117.88. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $54.65 billion, a price-to-earnings ratio of 105.25, a PEG ratio of 2.30 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the company earned $0.34 earnings per share. The company’s revenue for the quarter was up 26.9% compared to the same quarter last year. On average, equities analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. Citigroup boosted their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Raymond James boosted their price objective on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, UBS Group upped their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $141.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.